Report: Pipeline Insight: Cancer Overview - Lung, Brain, Head and Neck, Thyroid TOC

ABOUT DATAMONITOR HEALTHCARE
- About the Oncology pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the cancer market
- Contributing experts
- Related reports
- Upcoming reports
CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS
- Pipeline overview
  - Late-phase pipeline
  - Pipeline by indication
    - The higher-incidence tumor types remain the most popularindications for drug development
CHAPTER 3 R&D APPROACH
- Classification of pipeline products
  - Cytotoxics
  - Antihormonal therapies
  - Molecular targeted therapies
    - Single-target signal transduction inhibitors
    - Angiogenesis inhibitors
    - Apoptosis inducers
    - Cell cycle inhibitors
    - Multi-targeted inhibitors
    - Epigenetic modulators
  - Immunotherapeutic agents
CHAPTER 4 NON-SMALL CELL LUNG CANCER
- Overview of NSCLC
  - Definition
    - NSCLC accounts for about 80% of all lung cancers
  - Epidemiology
    - There will be more than 380,000 new cases of NSCLC in theseven major markets in 2017
    - Mortality from NSCLC is high
  - Treatment of NSCLC
- Unmet needs in NSCLC
  - Summary of unmet needs
    - Effective treatments are required for both advanced andearly-stage disease
    - NSCLC needs to be recognized as a heterogeneous disease
    - Less toxic treatments for poor performance status patientsare required
    - The treatment of NSCLC is in need of overall refinement
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Erbitux (cetuximab; ImClone/Merck Serono/Bristol-MyersSquibb)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Nexavar (sorafenib; Bayer Schering)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Sutent (sunitinib; Pfizer)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Tovok (BIBW 2992; Boehringer Ingelheim)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Vargatef (BIBF 1120; Boehringer-Ingelheim)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Zactima (vandetanib; AstraZeneca)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Zolinza (vorinostat; Merck & Co)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Aflibercept (VEGF-Trap; Sanofi-Aventis/Regeneron)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - ASA-404 (Antisoma/Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - CBT-1 (CBA Pharma)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - CP-751871 (Pfizer)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Motesanib (AMG706; Amgen/Takeda Pharmaceutical)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Abraxane (albumin-bound paclitaxel; Abraxis)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Glutoxim (NOV-002; Novelos)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Javlor (vinflunine; Pierre Fabre)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Lipoplatin (liposomal cisplatin; Regulon)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Taxoprexin (DHA paclitaxel; Luitpold)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Opaxio (paclitaxel polyglumex; Cell Therapeutics/Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Lucanix (NovaRx)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Stimuvax (BLP-25; Merck Serono)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - MAGE-A3 ASCI (GSK1572932A; GlaxoSmithKline)
    - Drug overview
    - Key historical events
    - Clinical development in NSCLC
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Approval of pipeline drugs will offer alternativetreatment options, however, are unlikely to significantly fulfil unmetneeds
CHAPTER 5 SMALL CELL LUNG CANCER
- Overview of SCLC
  - Definition
  - Epidemiology
    - The incidence of SCLC is decreasing with declining smokingprevalence
    - Poor survival rates result in a high mortality from SCLC
  - Treatment of SCLC
- Unmet needs in SCLC
  - Summary of unmet needs
    - There is a need for more effective systemic therapies toimprove patient survival
    - R&D activity in the field must be intensified
    - A better understanding of the molecular basis of thedisease may help in the development of novel targeted agents
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Picoplatin (AMD-473; Poniard Pharmaceuticals)
    - Drug overview
    - Key historical events
    - Clinical development in SCLC
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Picoplatin is unlikely to offer any significantimprovements in terms of patient survival
CHAPTER 6 MESOTHELIOMA
- Overview of mesothelioma
  - Definition
    - Mesothelioma is almost always caused by sustained exposureto asbestos
  - Epidemiology
    - Forecast incidence is difficult to predict formesothelioma, although the cancer is relatively rare
    - Survival rates for mesothelioma have improved minimallyover the years
  - Treatment of mesothelioma
- Unmet need in mesothelioma
  - Summary of unmet needs
    - Increasing incidence and need for earlier diagnosis
    - Low rate of curative surgery
    - Lack of approved therapies and low R&D interest
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Onconase (Alfacell Corp; ranpirnase)
    - Drug overview
    - Key historical events
    - Clinical development in mesothelioma
    - Datamonitor comments
  - Zolinza (vorinostat; Merck & Co)
    - Drug overview
    - Key historical events
    - Clinical development in mesothelioma
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Onconase and Zolinza meet some unmet needs in terms ofproviding much needed alternative treatment options
CHAPTER 7 PRIMARY BRAIN CANCER
- Overview of primary brain cancer
  - Definition
    - Glioma is the most common type of primary brain cancer
  - Epidemiology
    - Incidence of brain cancer is rising in line with theageing population
    - Mortality from brain cancer is very high in comparison toits incidence
  - Treatment of primary brain cancer
- Unmet need in primary brain cancer
  - Summary of unmet needs
    - More effective chemotherapy options needed
    - Blood-brain barrier may prove an obstacle to overcome
    - Need for neuroprotective therapy
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Theraloc (nimotuzumab; YM Biosciences/BioconBiopharmaceuticals)
    - Drug overview
    - Key historical events
    - Clinical development in brain cancer
    - Datamonitor comments
  - Cerepro (sitimagene ceradenovec; Ark Therapeutics)
    - Drug overview
    - Key historical events
    - Clinical development in brain cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Temodar will retain its leading status for some time tocome in the primary brain cancer market
CHAPTER 8 HEAD AND NECK CANCER
- Overview of head and neck cancer
  - Definition
    - Head and neck cancers comprise around 6% of all tumorsworldwide
  - Epidemiology
    - Incidence will continue to rise in line with the ageingpopulation
    - Mortality is high due to frequent late-stage diagnosis andlack of effective treatments
  - Treatment of head and neck cancer
- Unmet need in head and neck cancer
  - Summary of unmet needs
    - Currently available therapies induce modest response rates
    - High level of treatment-related morbidity and poor qualityof life
    - Early-stage diagnosis is limited, thereby compromisingsurvival
    - High economic burden
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Avastin (bevacizumab; Genentech/Roche/Chugai)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Tykerb (lapatinib; GlaxoSmithKline)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Vectibix (panitumumab; Amgen)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Zalutumumab (HuMax-EGFR; Genmab/Medarex)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Alimta (pemetrexed; Eli Lilly)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Lipoplatin (liposomal cisplatin; Regulon)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Multikine (mixture of naturally occurring cytokines; CEL-SCI)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Proxinium (VB4-845; Viventia Biotech)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Advexin (contusugene; Introgen Therapeutics)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - INGN-241 (Introgen Therapeutics)
    - Drug overview
    - Key historical events
    - Clinical development in head and neck cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Superiority over current standard therapies is unlikely tobe shown by the current pipeline
CHAPTER 9 THYROID CANCER
- Overview of thyroid cancer
  - Definition
    - Thyroid cancer occurs more frequently in women and at ayounger age
  - Epidemiology
    - Incidence of thyroid cancer is rising due to increasinguse of ultrasound to detect small tumors
    - Thyroid cancer is one of the least deadly tumor types
  - Treatment of thyroid cancer
- Unmet need in thyroid cancer
  - Summary of unmet need
    - R&D interest is exceedingly low
    - Few alternative treatment options exist upon diseaserecurrence
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Zybrestat (combretastatin; OXiGENE)
    - Drug overview
    - Key historical events
    - Clinical development in thyroid cancer
    - Datamonitor comments
  - Axitinib (AG-13736; Pfizer)
    - Drug overview
    - Key historical events
    - Clinical development in thyroid cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Axitinib and Zybrestat could form viable therapies wherefew alternative treatment options exist
APPENDIX A
- Bibliography
- List of tables
- List of figures
- List of abbreviations
- Methodology
  - Datamonitor forecast methodology
    - Epidemiology forecasts
    - Product forecasts
  - Datamonitor drug assessment summary
APPENDIX B
- About Datamonitor
  - About Datamonitor Healthcare
- Datamonitor Healthcare' s therapy area capabilities
  - About the Disease analysis team
  - Disclaimer
List of Tables
- Table 1: Late-phase cytotoxics pipeline for NSCLC, SCLC,mesothelioma, primary brain cancer, head and neck cancer, and thyroidcancer, 2008
- Table 2: Late-phase targeted therapies pipeline forNSCLC, SCLC, mesothelioma, primary brain cancer, head and neck cancer, andthyroid cancer, 2008
- Table 3: Late-phase immunotherapies pipeline for NSCLC,SCLC, mesothelioma, primary brain cancer, head and neck cancer, andthyroid cancer, 2008
- Table 4: Late-phase gene therapies pipeline for NSCLC,SCLC, mesothelioma, primary brain cancer, head and neck cancer, andthyroid cancer, 2008
- Table 5: Pipeline split by developmental phase andindication, 2008
- Table 6: Forecast incidence of NSCLC in the seven majorpharmaceutical markets, 2002-2017
- Table 7: Phase III NSCLC pipeline, 2008 (targetedtherapies)
- Table 8: Phase III NSCLC pipeline, 2008 (cytotoxic andimmunotherapies)
- Table 9: Phase II NSCLC pipeline, 2008 (targetedtherapies)
- Table 10: Phase II NSCLC pipeline, 2008 (cytotoxics)
- Table 11: Phase II NSCLC pipeline, 2008 (immunotherapiesand others)
- Table 12: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (molecular targetedtherapies, 1 of 4)
- Table 13: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (molecular targetedtherapies, 2 of 4)
- Table 14: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (molecular targetedtherapies, 3 of 4)
- Table 15: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (molecular targetedtherapies, 4 of 4)
- Table 16: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (cytotoxic therapies, 1 of2)
- Table 17: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (cytotoxic therapies, 2 of2)
- Table 18: Forecasting assumptions for NSCLC pipelineproducts across the seven major markets, 2008 (immunotherapies)
- Table 19: Pipeline NSCLC product sales forecasts acrossthe seven major markets, 2008-2017 ($m)
- Table 20: Avastin: key historical facts
- Table 21: Taxotere: key historical facts
- Table 22: Erbitux: key historical events
- Table 23: Clinical development of Erbitux in NSCLC, 2008
- Table 24: Preliminary results of Erbitux withcarboplatin and a taxane in first-line NSCLC (BMS-099)
- Table 25: Nexavar: key historical events
- Table 26: Clinical development of Nexavar in NSCLC, 2008
- Table 27: Sutent: key historical events
- Table 28: Clinical development of Sutent in NSCLC, 2008
- Table 29: Tovok: key historical events
- Table 30: Clinical development of Tovok in NSCLC, 2008
- Table 31: Vargatef: key historical events
- Table 32: Zactima' s multiple anticancer targets
- Table 33: Zactima: key historical events
- Table 34: Clinical development of Zactima in NSCLC, 2008
- Table 35: Zolinza: key historical events
- Table 36: Clinical development of Zolinza in NSCLC, 2008
- Table 37: Aflibercept: key historical events
- Table 38: Clinical development of aflibercept in NSCLC,2008
- Table 39: ASA-404: key historical events
- Table 40: Clinical development of ASA-404 in NSCLC, 2008
- Table 41: CBT-1: key historical events
- Table 42: Clinical development of CBT-1 in NSCLC, 2008
- Table 43: CP-751871: key historical events
- Table 44: Clinical development of CP-751871 in NSCLC,2008
- Table 45: Motesanib: key historical events
- Table 46: Clinical development of motesanib in NSCLC,2008
- Table 47: Abraxane: key historical events
- Table 48: Clinical development of Abraxane in NSCLC,2008
- Table 49: Glutoxim: key historical events
- Table 50: Clinical development of Glutoxim in NSCLC,2008
- Table 51: Javlor: key historical events
- Table 52: Clinical development of Javlor in NSCLC, 2008
- Table 53: Lipoplatin: key historical events
- Table 54: Clinical development of Lipoplatin in NSCLC,2008
- Table 55: Taxoprexin: key historical events
- Table 56: Clinical development of Taxoprexin in NSCLC,2008
- Table 57: Opaxio: key historical events
- Table 58: Clinical development of Opaxio in NSCLC, 2008
- Table 59: STELLAR 2: Phase III results for Opaxio versusTaxotere in second-line NSCLC in patients with PS0-2
- Table 60: STELLAR 3: Phase III results for Opaxio pluscarboplatin in first-line NSCLC in patients with PS2
- Table 61: STELLAR 4: Phase III results for Opaxio versusGemzar or vinorelbine in first-line NSCLC in patients with PS2
- Table 62: Clinical development of Opaxio in women withadvanced NSCLC and normal estrogen levels: the PTG306 and PTG307 trials
- Table 63: Lucanix: key historical events
- Table 64: Clinical development of Lucanix in NSCLC, 2008
- Table 65: Stimuvax: key historical events
- Table 66: Clinical development of Stimuvax in NSCLC,2008
- Table 67: MAGE-A3 ASCI: key historical events
- Table 68: Clinical development of MAGE-A3 ASCI in NSCLC,2007
- Table 69: Classification of SCLC: the Veteran' sAdministration Lung Cancer Study Group (VALCSG) staging system
- Table 70: Datamonitor' s forecast incidence of SCLC inthe seven major pharmaceutical markets, 2002-2017
- Table 71: Phase III SCLC pipeline, 2008
- Table 72: Phase II SCLC pipeline, 2008 (targetedtherapies)
- Table 73: Phase II SCLC pipeline, 2008 (cytotoxics andimmunotherapies)
- Table 74: Forecasting assumptions for picoplatin in SCLCacross the seven major pharmaceutical markets, 2008
- Table 75: Picoplatin sales forecasts across the sevenmajor markets, 2008-2017 ($m)
- Table 76: Hycamtin: key historical facts
- Table 77: Picoplatin: key historical events
- Table 78: Clinical development of picoplatin in SCLC,2008
- Table 79: Epidemiologic features of malignantmesothelioma, 2005
- Table 80: Late-phase mesothelioma pipeline, 2008
- Table 81: Phase II mesothelioma pipeline, 2008
- Table 82: Forecasting assumptions for pipelinemesothelioma products across the seven major markets, 2008
- Table 83: Pipeline mesothelioma product sales forecastsacross the seven major markets, 2008-2017 ($m)
- Table 84: Alimta: key facts
- Table 85: Onconase: key historical events
- Table 86: Zolinza: key historical events
- Table 87: Clinical development of Zolinza inmesothelioma, 2008
- Table 88: Estimated incidence of brain cancer in theseven major pharmaceutical markets, 2002-2017
- Table 89: Phase III brain cancer pipeline, 2008
- Table 90: Phase II brain cancer pipeline, 2008 (targetedtherapies)
- Table 91: Phase II brain cancer pipeline, 2008(cytotoxics)
- Table 92: Phase II brain cancer pipeline, 2008 (others)
- Table 93: Forecasting assumptions for pipeline braincancer products across the seven major markets, 2008
- Table 94: Pipeline brain cancer product sales forecastsacross the seven major markets, 2008-2017 ($m)
- Table 95: Temodar: key facts
- Table 96: Theraloc: key historical events
- Table 97: Clinical development of Theraloc in braincancer, 2008
- Table 98: Cerepro: key historical events
- Table 99: Clinical development of Cerepro in braincancer, 2008
- Table 100: Risk factors for subtypes of head and neckcancer
- Table 101: Estimated incidence of head and neck cancerin the seven major pharmaceutical markets, 2002-2017
- Table 102: Phase III head and neck cancer pipeline, 2008
- Table 103: Phase II head and neck cancer pipeline, 2008(targeted therapies)
- Table 104: Phase II head and neck cancer pipeline, 2008(cytotoxics)
- Table 105: Phase II head and neck cancer pipeline, 2008(others)
- Table 106: Forecasting assumptions for pipeline head andneck cancer products across the seven major markets, 2008 (1 of 3)
- Table 107: Forecasting assumptions for pipeline head andneck cancer products across the seven major markets, 2008 (2 of 3)
- Table 108: Forecasting assumptions for pipeline head andneck cancer products across the seven major markets, 2008 (3 of 3)
- Table 109: Pipeline head and neck cancer product salesforecasts across the seven major markets, 2008-2017 ($m)
- Table 110: Erbitux: key facts
- Table 111: Avastin: key historical events
- Table 112: Clinical development of Avastin in head andneck cancer, 2008
- Table 113: Tarceva: key historical events
- Table 114: Clinical development of Tarceva in head andneck cancer, 2008
- Table 115: Tykerb: key historical events
- Table 116: Clinical development of Tykerb in head andneck cancer, 2008
- Table 117: Vectibix: key historical events
- Table 118: Clinical development of Vectibix in head andneck cancer, 2008
- Table 119: Zalutumumab: key historical events
- Table 120: Clinical development of zalutumumab in headand neck cancer, 2008
- Table 121: Alimta: key historical events
- Table 122: Clinical development of Alimta in head andneck cancer, 2008
- Table 123: Lipoplatin: key historical events
- Table 124: Clinical development of Lipoplatin in headand neck cancer, 2008
- Table 125: Multikine: key historical events
- Table 126: Clinical development of Multikine in head andneck cancer, 2008
- Table 127: Proxinium: key historical events
- Table 128: Clinical development of Proxinium in head andneck cancer, 2008
- Table 129: Advexin: key historical events
- Table 130: Clinical development for Advexin in head andneck cancer, 2008
- Table 131: INGN-241: key historical events
- Table 132: Estimated incidence of thyroid cancer in theseven major pharmaceutical markets, 2002-2017
- Table 133: Five-year survival rates by stage of thyroidcancer
- Table 134: Phase III thyroid cancer pipeline, 2008
- Table 135: Phase II thyroid cancer pipeline, 2008
- Table 136: Forecasting assumptions for pipeline thyroidcancer products across the seven major markets, 2008
- Table 137: Pipeline thyroid cancer product salesforecasts across the seven major markets, 2008-2017 ($m)
- Table 138: Doxil: key facts
- Table 139: Zybrestat: key historical events
- Table 140: Clinical development of Zybrestat in thyroidcancer, 2008
- Table 141: Axitinib: key historical events
- Table 142: Phase II development of axitinib in thyroidcancer, 2007
- Table 143: List of abbreviations
- Table 144: Datamonitor drug assessment parameters
List of Figures
- Figure 1: Forecast incidence and mortality from NSCLC in2008 and 2017 across the seven major markets
- Figure 2: The role of surgery, chemotherapy andradiotherapy in the management of NSCLC
- Figure 3: Summary of unmet needs in the NSCLC market
- Figure 4: Datamonitor drug assessment summary for themolecular targeted therapies in late-phase development for NSCLC, 2008
- Figure 5: Datamonitor drug assessment summary for thecytotoxic therapies in late-phase development for NSCLC, 2008
- Figure 6: Datamonitor drug assessment summary for theimmunotherapies in late-phase development for NSCLC, 2008
- Figure 7: Pipeline NSCLC targeted therapies salesforecasts across the seven major markets, 2008-2017 ($m)
- Figure 8: Pipeline NSCLC cytotoxic therapies salesforecasts across the seven major markets, 2008-2017 ($m)
- Figure 9: Pipeline NSCLC immunotherapies sales forecastsacross the seven major markets, 2008-2017 ($m)
- Figure 10: Phase III FLEX trial results
- Figure 11: Phase II results for first-line Erbitux withchemoradiotherapy in locally advanced NSCLC
- Figure 12: Phase II results for Nexavar monotherapy insecond- or third-line NSCLC
- Figure 13: Phase II results of third-line Nexavarmonotherapy: randomized discontinuation design
- Figure 14: Phase II results for Sutent monotherapy insecond- or third-line NSCLC
- Figure 15: Phase I results for Tovok in patients withadvanced solid malignancies
- Figure 16: Phase II results for Vargatef monotherapy insecond- or third-line NSCLC
- Figure 17: Phase II results for Zactima with carboplatinand paclitaxel in first-line NSCLC
- Figure 18: Phase II results for Zactima with Taxotere insecond-line NSCLC
- Figure 19: Phase II results for Zactima versus Iressa inadvanced NSCLC
- Figure 20: Phase III studies of Zactima in NSCLC
- Figure 21: Phase II results for Zolinza monotherapy insecond-line NSCLC
- Figure 22: Interim Phase II results for afliberceptmonotherapy in third-line NSCLC
- Figure 23: Phase II results for ASA-404 withchemotherapy in first-line NSCLC
- Figure 24: Phase Ib/II results for ASA-404 withchemotherapy in first-line NSCLC
- Figure 25: Interim Phase II results for CP-751871 withchemotherapy in first-line NSCLC
- Figure 26: Phase Ib results for motesanib withcarboplatin and paclitaxel or Vectibix in first- or second-line NSCLC
- Figure 27: Interim Phase II results for Abraxane withcarboplatin and Avastin in first-line NSCLC
- Figure 28: Phase II results for Abraxane monotherapy infirst-line NSCLC
- Figure 29: Phase I/II results for Glutoxim withchemotherapy in first-line NSCLC
- Figure 30: Phase III results for Javlor versus Taxoterein second-line NSCLC
- Figure 31: Interim Phase III results for Lipoplatin withGemzar in first-line NSCLC
- Figure 32: Interim Phase III results for Lipoplatin withpaclitaxel in first-line NSCLC
- Figure 33: Phase II results for Taxoprexin monotherapyin first-line NSCLC
- Figure 34: Phase II results for Lucanix in advancedNSCLC
- Figure 35: Phase IIb results for Stimuvax maintenancetherapy in advanced NSCLC
- Figure 36: Phase II results for MAGE-A3 ASCI as adjuvanttherapy in completely resected Stage IB/II NSCLC
- Figure 37: Forecast incidence and mortality from NSCLCin 2008 and 2017 across the seven major markets
- Figure 38: Overview of SCLC treatment
- Figure 39: Summary of unmet needs in the SCLC market
- Figure 40: Datamonitor drug assessment summary forpicoplatin in SCLC, 2008
- Figure 41: Picoplatin sales forecasts across the sevenmajor markets, 2008-2017 ($m)
- Figure 42: Phase II results for picoplatin insecond-line SCLC
- Figure 43: Five-year survival rates for mesothelioma inthe US, 1975-1998
- Figure 44: Summary of unmet needs in the mesotheliomamarket
- Figure 45: Datamonitor drug assessment summary for thepipeline mesothelioma products, 2008
- Figure 46: Pipeline mesothelioma product sales forecastsacross the seven major markets, 2008-2017 ($m)
- Figure 47: Phase III results for first- or second-linedoxorubicin with or without Onconase in mesothelioma patients
- Figure 48: Phase I results for second-line Zolinza inmesothelioma patients
- Figure 49: Incidence and mortality from brain cancer in2008 and 2017 across the seven major markets
- Figure 50: Summary of unmet needs in the primary braincancer market
- Figure 51: Datamonitor drug assessment summary for thepipeline brain cancer products, 2008
- Figure 52: Pipeline brain cancer product sales forecastsacross the seven major markets, 2008-2017 ($m)
- Figure 53: Phase II results for Theraloc in relapsed orrefractory pediatric high-grade gliomas
- Figure 54: Phase II trial investigating Cerepro inprimary and recurrent glioma patients
- Figure 55: Incidence and mortality from head and neckcancer in 2008 and 2017 across the seven major markets
- Figure 56: Summary of unmet needs in the head and neckcancer market
- Figure 57: Datamonitor drug assessment summary for thepipeline head and neck cancer products, 2008
- Figure 58: Pipeline head and neck cancer product salesforecasts across the seven major markets, 2008-2017 ($m)
- Figure 59: Phase II results for first-line Alimta andAvastin in advanced head and neck cancer
- Figure 60: Phase II study investigating Avastin withconcurrent radiotherapy and Taxotere in head and neck cancer
- Figure 61: Interim Phase II results for first-lineTarceva, Taxotere and cisplatin in metastatic or recurrent head and neckcancer
- Figure 62: Phase II results for first-line Tarceva,cisplatin and radiotherapy for locally advanced head and neck cancer
- Figure 63: Phase II results for third-line Tykerb inrecurrent or metastatic head and neck cancer
- Figure 64: Preliminary Phase I results for first-lineVectibix and chemoradiotherapy in Stage III/IV head and neck cancer
- Figure 65: Phase I/II trial results for second-linezalutumumab in patients with recurrent squamous cell head and neck cancer
- Figure 66: Phase II results for first-line Alimta andAvastin in advanced head and neck cancer
- Figure 67: Phase II results for first-line Alimta inadvanced head and neck cancer
- Figure 68: Phase II trial and follow-up results forneoadjuvant Multikine in head and neck cancer
- Figure 69: Interim Phase III results for second-lineProxinium in advanced head and neck cancer
- Figure 70: Phase I dose-escalation trial for Proxiniumin advanced head and neck cancer
- Figure 71: Preliminary results from the Phase III T301study comparing second-line Advexin with methotrexate in recurrent headand neck cancer
- Figure 72: Incidence and mortality from thyroid cancerin 2008 and 2017 across the seven major markets
- Figure 73: Summary of unmet needs in the thyroid cancermarket
- Figure 74: Datamonitor drug assessment summary for thepipeline thyroid cancer products, 2008
- Figure 75: Pipeline thyroid cancer product salesforecasts across the seven major markets, 2008-2017 ($m)
- Figure 76: Phase II results for first-line Zybrestat inadvanced anaplastic thyroid cancer patients
- Figure 77: Phase II results for axitinib in thyroidcancer patients refractory or unsuitable for radioiodine therapy
- Figure 78: Datamonitor drug assessment summary ofpipeline molecular targeted therapies in development for hematologicalmalignancies, 2007

Pipeline Insight: Cancer Overview - Lung, Brain, Head and Neck, Thyroid

Table of Contents